New Horizon Raises $20 Million for Diagnostics in Qiming-Led B Round

01:17 EDT 10 Aug 2017 | ChinaBio Today

New Horizon Health, a Beijing-Hangzhou company developing early-stage cancer screening products, raised $20 million in a B round led by Qiming Venture Partners. New Horizon's first product is a home-based test for colorectal cancer using fecal gene analysis (FIT-DNA) technology. Horizon believes the test can detect precancerous lesions five years earlier than blood tests. Using a colonoscopy, the lesions can be removed before they become cancerous. Previous investors Legend Capital and SoftBank China also participated in the B round. More details....

Share this with colleagues:

Original Article: New Horizon Raises $20 Million for Diagnostics in Qiming-Led B Round


More From BioPortfolio on "New Horizon Raises $20 Million for Diagnostics in Qiming-Led B Round"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...